For more than a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations. The biology looked promising. Many cancers depend on oncogenes that “Bromo- and Extra-Terminal domain” (BET) proteins help activate, so blocking BET proteins should slow tumor growth.

Amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand (OX40L), is safe and effective, with potentially progressive efficacy over time, for patients with moderate-to-severe atopic dermatitis (AD), according to the results of three phase 3 studies presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver.

A new report investigates the technological frontline of the war on health misinformation. The article, “As Social Media Scales Back Fact-Checking, Can Technologies Fill the Gap?” by Wendy Glauser examines the shift from professional oversight to democratized and AI-driven moderation at a time when deepfakes and generative AI are accelerating the spread of life-threatening medical myths. The findings are published in the Journal of Medical Internet Research.

Health officials are changing the rules for who can serve on a key vaccine advisory panel after a judge ruled that many current members are unqualified.

Australia’s population is projected to age over the next 40 years and the number of centenarians is expected to increase six-fold. The number of Australians aged 65 and over will more than double, and the number of citizens aged 65 and over will more than triple. Data from the Australian Institute of Health and Welfare revealed 1 in 12 people aged 65 and over have dementia, rising to 2 in 5 for those aged 90 and over. This has prompted calls for the widespread introduction of dementia education in the education and training of health professionals.